VVOSVivos Therapeutics, Inc.

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index decreasing 0.9% a

Company projects a clear path to positive cash flow by late 2026 or early 2027 despite ongoing net losses and going concern risk.

Vivos Therapeutics Inc. (NASDAQ:VVOS) shares fell 6.

Moby summary of Vivos Therapeutics, Inc.'s Q2 2026 earnings call

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +26.19% and -5.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -51.63% and +5.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The newly issued patent broadens intellectual property protection for Vivos’ flagship oral medical device platform, reinforcing its competitive position in the obstructive sleep apnea treatment market. Key Investor TakeawaysVivos Therapeutics (NASDAQ:VVOS) received a new U.

The latest update on Vivos Therapeutics centers on a trimmed fair value estimate, with the price target moving from about US$2.45 to roughly US$2.12 per share. This shift lines up with recent Street commentary that has paired cautious or Neutral ratings with lower targets, as analysts weigh balance sheet concerns and potential equity dilution against ongoing clinical and commercial efforts. Read on to see what is driving these price target resets and how to track the evolving narrative around...